Tag: #LAM
Guardant to develop CDx and TMB liquid biopsy tests for AstraZeneca’s targeted cancer therapies
| Fierce Biotech

AstraZeneca has tapped Guardant Health to develop blood-based companion diagnostics for its cancer treatments Tagrisso and Imfinzi. Under the multiyear agreement, Guardant will pursue an FDA approval for a Guardant360 CDx liquid biopsy test to help identify non-small cell lung cancer patients for treatment with Tagrisso, an EGFR inhibitor.